Anti-cancer black technology: electric field therapy can treat liver cancer, brain cancer and breast cancer

In layman's terms, electric field therapy is a physical therapy based on bioelectricity

One reason that glioma is difficult to treat is because it hides in the brain and is protected by the blood-brain barrier, so many drugs cannot enter it

TTFields treatment technology comes from Novocure founder Dr.

Since its inception, electric field therapy has received extensive attention from the medical community, not only because its principles have never been heard before, but also because such a fantasy technology is not a big flash point, but is based on several rounds of facts

In 2011, the FDA approved electric field therapy for the treatment of recurrent glioblastoma;

In 2016, the FDA approved the electric field to treat newly diagnosed glioblastoma;

In 2019, the FDA approved electric field therapy to treat mesothelioma

At present, this anti-cancer black technology is expected to make a breakthrough in a more promising market

Although no specific details were disclosed, the stock prices of Novocure and Zai Lab, which owns the commercialization rights of Optune products in China, rose sharply due to the impact of the news, and their market value increased by a total of 9.

This shows that the prospect of electric field treatment of tumors is very broad

The disease control rate is as high as 91%! Electric field therapy successfully challenged liver cancer and brought a new dawn!

The mortality rate of liver cancer has always been relatively high, but the detection rate of early liver cancer is very low

At this time, the opportunity for surgical treatment has been lost, resulting in a 5-year survival rate of only 12%

At present, for patients with advanced disease and advanced local treatment, the general standard treatment is systemic treatment of sorafenib, levuvatinib or atezizumab plus bevacizumab

However, these therapies have two unavoidable problems

Therefore, new therapies with better efficacy, safety, non-invasiveness and long-term effectiveness are being developed all over the world

Novocure announced on July 1, 2021 that its Phase 2 clinical trial HEPANOVA, which combines electric field therapy with sorafenib for the treatment of liver cancer, has achieved positive results

It is worth mentioning that the patients with advanced liver cancer selected this time are all clinically extremely difficult to treat

The test results showed that 21 patients with evaluable poor prognosis, the disease control rate was 76% (the historical control group was 43% ~ 52%), and the objective remission rate was 9.
5%;

Among the patients who completed the tumor electric field treatment for more than 12 weeks, the disease control rate was 91%, and the objective remission rate was 18%, both higher than the historical control group
.

In the next step, Novocure plans to initiate a key phase 3 trial to explore the efficacy of tumor electric field therapy combined with standard treatments (including immunotherapy) for liver cancer patients
.

Tumor treatment electric field, as a new treatment for the first time in 15 years, has been approved as a first-line treatment for mesothelioma

On May 24, 2019, Novocure announced that the US FDA approved the company's NovoTTF-100L system in combination with pemetrexed and platinum-based chemotherapy for unresectable locally advanced or metastatic malignant pleural mesothelioma (MPM) First-line treatment
.

NovoTTF-100L is a non-invasive, anti-mitotic cancer treatment that uses a tumor treatment electric field to treat the tumor area
.
It is worth noting that NovoTTF-100L is the first new MPM drug approved by the FDA in 15 years
.

MPM is a rare cancer caused by exposure to asbestos
.
Before the FDA approved NovoTTF-100L, the combination of pemetrexed and cisplatin was the only approved treatment for unresectable MPM
.

In this single-group clinical trial, 80 patients with MPM received first-line treatment with a combination therapy consisting of NovoTTF-100L and chemotherapy
.

The results of the trial showed that the median overall survival of patients receiving the combination therapy was 18.
2 months
.
62% of patients were still alive after receiving the combination therapy for 1 year
.

Among patients who had received at least one CT follow-up, the disease control rate reached 97%, and the partial remission rate was 40%
.

MPM is a catastrophic disease
.
Only 10% to 20% of patients can undergo surgery to remove the tumor
.
Generally speaking, patients with mesothelioma who cannot undergo surgery can only rely on palliative care to relieve their symptoms
.
NovoTTF-100L provides them with a treatment option that may improve survival
.

"Detonate" cancer cells! Electric field treatment doubles the 5-year survival rate!

This therapy is called "anti-cancer black technology" because its principle is different from traditional treatment methods such as surgery, drug therapy, and radiation therapy
.

Principle of treatment

Electric field therapy uses the special electrical properties of cancer cells, and uses electric fields to interfere with the division of cancer cells and ultimately lead to the death of cancer cells
.
It can kill cancer cells while ensuring that healthy cells are basically not harmed
.

Although this principle is simple, it is actually extremely complicated
.
This is the most sci-fi anti-cancer therapy in history
.

At present, electric field therapy has been approved by the FDA for the treatment of recurrent glioblastoma, newly diagnosed glioblastoma, and malignant pleural mesothelioma.
It is currently used for six major types of non-small cell lung cancer and non-small cell lung cancer.
Solid tumors
.
Surprising data have been obtained in clinical trials of lung cancer, brain metastases, liver cancer, pancreatic cancer, ovarian cancer and breast cancer
.
Since its principle is to target and kill all fast mitotic cancer cells, it is theoretically applicable to all solid tumors
.

Clinical data

It is worth mentioning that this "all-round dark horse" has been clinically proven to be more suitable for Asian patients
.
In the internationally renowned EF-14 trial, during the 5-year follow-up period, regardless of health status, age, gender and tumor size, the electric field treatment plus chemotherapy group survived longer
.
The 5-year survival rate is as high as 13%, compared with only 5% in the chemotherapy group
.
The treatment effect is two times ahead, which is absolutely unprecedented
.

Among them, in the entire EF-14 experiment, the difference in survival rate of Asian patients receiving electric field treatment is higher than that of people receiving electric field treatment (1 year survival rate 95.
6% vs 73%, 2-year survival rate 59.
9% vs 43%)
.
This further shows that Asian patients can benefit more from electric field therapy
.

Reference website:

https:// Cancer

(Source: Internet, for reference only)